Business
-
Intranasal hydrogel maker Polyrizon announced that it has closed a $4.2 million IPO, with a possibility of the total rising to $4.82 million if Aegis Capital exercises an option to purchase additional shares. Polyrizon said… Read more . . .
-
AuraVax Therapeutics announced that the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a preclinical research contract to support evaluation of AuraVax’s NanoSTING-002 mucosal adjuvant… Read more . . .
-
French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company’s pipeline includes nasal vaccines against zoonotic diseases… Read more . . .
-
Agomab Therapeutics said that it has closed an $89 million Series D financing round that will support development of several candidates, including its AGMB-447 inhaled ALK5 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF).… Read more . . .
-
Honeywell announced that it has signed a long-term supply agreement with DevPro Biopharma related to the use of Honeywell’s Solstice Air HFO-1234ze in DevPro’s DP007 albuterol metered dose inhaler. Earlier this year, DevPro and CDMO… Read more . . .
-
Liquidia Corporation will pay Pharmosa $3.5 million up front plus as much as $157.75 million in milestone payments to extend their existing agreement related to L606 inhaled liposomal treprostinil for the treatment of pulmonary arterial hypertension… Read more . . .
-
According to InCarda, data from the Phase 3 RESTORE-1 trial of FlecIH-103 flecainide inhalation solution for aroxysmal atrial fibrillation (PAF), which was initiated in July 2022, support continued development despite the early termination of the… Read more . . .
-
ARS Pharmaceuticals has launched Neffy epinephrine nasal spray in the US, the company said. In Auguest 2024, Neffy was approved by the FDA for the treatment of anaphylaxis in patients who weigh 30 kg or… Read more . . .
-
PureIMS has announced that personalized medicine company Fagron has acquired exclusive rights to distribute PureIMS’s Cyclops dry powder inhaler with compounded inhalation powders in the Netherlands. The Cyclops DPIs, which are pre-filled with drug, will be… Read more . . .
-
Tiziana Life Sciences announced that a study of the company’s intranasal anti-CD3 mAb will be funded by a $4 million grant from the National Institutes of Health. In June 2024, the company said that the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland